Erin Gautier Doty

Donanemab for early symptomatic AD in the UK-indicated population: safety and efficacy in those who are non-carriers or heterozygous for APOE ε4

Nuha Brookfield, Paula M. Hauck, Erin Gautier Doty, Jennifer A. Zimmer et autres

Background Licensing of donanemab in the United Kingdom (UK) for the treatment of early symptomatic Alzheimer’s disease is limited to adults who are Apolipoprotein E (APOE) ε4 non-carriers or heterozygotes.Aim To assess safety and efficacy of donanemab in the UK-indicated population.Methods Post-hoc …

us (code pays fourni par la source)

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease

Alireza Atri, Liana G. Apostolova, Atsushi Iwata, Alette M. Wessels et autres

BACKGROUND AND OBJECTIVES: Understanding the meaningfulness of clinical trial outcomes is essential for people living with Alzheimer disease (AD) and their clinicians to make evidence-based shared treatment decisions in real-world clinical care. Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid …

us, jp (code pays fourni par la source)

The importance of early recognition and treatment initiation for managing Alzheimer's disease: Subpopulation analysis of the TRAILBLAZER-ALZ 2 randomized trial

Raghavendra Vasudeva, Erin Gautier Doty, Fan Yang, Cynthia D. Evans et autres

us (code pays fourni par la source)

Towards Identifying an Optimal Time for Amyloid Assessment with Donanemab Treatment (S23.004)

Jared R. Brosch, Erin Gautier Doty, Ivelina Gueorguieva, Sergey Shcherbinin et autres

Elucidate the optimal timing for assessing a patient’s amyloid level in response to donanemab treatment through the use of real-world data.

us (code pays fourni par la source)

The Importance of Early Recognition and Treatment Initiation for Managing Alzheimer’s disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial (S23.005)

Raghavendra Vasudeva, Erin Gautier Doty, Fan Yang, Cynthia Duggan Evans et autres

To assess efficacy and safety of donanemab in participants at earlier clinical (mild cognitive impairment [MCI]) and pathological (low-medium tau) stages of Alzheimer’s disease (AD).

us (code pays fourni par la source)

Application of the revised criteria for diagnosis and staging of Alzheimer's disease: Drug development and clinical practice

Clifford R. Jack, Ana Graf, Samantha C. Burnham, Erin Gautier Doty et autres

The newly proposed revised criteria for diagnosis and staging of Alzheimer's disease (AD) by the Alzheimer's Association (AA) Workgroup represent a significant milestone in the field. These criteria offer objective measures for diagnosing and staging biological AD, bridging the gap between research …

us, ch, dk (code pays fourni par la source)

Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer’s Disease in the United States

Malaz A. Boustani, Erin Gautier Doty, Louis P. Garrison, Lee J. Smolen et autres

INTRODUCTION: The goal of this economic model is to estimate an economically justifiable price (EJP) for using donanemab for the treatment of early symptomatic Alzheimer's disease (AD) in the United States based on clinical data from the phase 3 TRAILBLAZER-ALZ 2 trial …

us, gb (code pays fourni par la source)

Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer’s Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study

Julie Chandler, Wenyu Ye, Xiaojuan Mi, Erin Gautier Doty et autres

Background: Impact of Alzheimer's disease (AD) progression on patient health-related quality of life (HRQoL), caregiver time, and societal costs is not well characterized in early AD. Objective: To assess the association of change in cognition with HRQoL, caregiver time, and societal costs …

us (code pays fourni par la source)

Clinical Relevance of Donanemab Treatment (S1.004)

Alireza Atri, Alette M. Wessels, Erin Gautier Doty, Alexandra S. Atkins et autres

To assess in Alzheimer’s disease (AD), the treatment impact of donanemab, an amyloid plaque-reducing monoclonal antibody, on readily interpretable item-measures and constructs that matter to patients, care-partners, and clinicians1–3.

us, sg (code pays fourni par la source)

Serotonin syndrome in the acute treatment landscape of migraine: the lasmiditan experience

Andrew M. Blumenfeld, Stewart J. Tepper, Rashna Khanna, Erin Gautier Doty et autres

Background: receptor agonist for acute treatment of migraine. Because SS symptoms are heterogeneous, diagnosis can be challenging, and potential cases observed with lasmiditan treatment led to questions about SS pathophysiology. Here, we provide an overview of the potential risk of SS based …

us, gb (code pays fourni par la source)

Potential Savings in Caregiver Time and Societal Costs Associated with Slowing Disease Progression over 36 months in Patients with Early Alzheimer’s Disease: Findings from GERAS‐US

Julie Chandler, Wenyu Ye, Joseph Andrew Johnston, Xiaojuan Mi et autres

Abstract Background Alzheimer’s disease (AD) is associated with significant costs that increase with disease progression. These analyses describe the relationship between cognitive decline and measures of caregiver time and societal costs and estimate the impact of slowing disease progression over 36 months. …

us (code pays fourni par la source)

Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease

Malaz A. Boustani, Erin Gautier Doty, Louis P. Garrison, Lee J. Smolen et autres

PURPOSE: Clinical trials have produced promising results for disease-modifying therapies (DMTs) for Alzheimer's disease (AD); however, the evidence on their potential cost-effectiveness is limited. This study assesses the cost-effectiveness of a hypothetical DMT with a limited treatment duration in AD. METHODS: We …

us, gb (code pays fourni par la source)